Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jul;9(7):e002646.
doi: 10.1136/jitc-2021-002646.

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Sandra P D'Angelo  1   2 , Celeste Lebbé  3 , Laurent Mortier  4 , Andrew S Brohl  5 , Nicola Fazio  6 , Jean-Jacques Grob  7 , Natalie Prinzi  8 , Glenn J Hanna  9 , Jessica C Hassel  10 , Felix Kiecker  11 , Sara Georges  12 , Barbara Ellers-Lenz  13 , Parantu Shah  12 , Gülseren Güzel  14 , Paul Nghiem  15
Affiliations
Clinical Trial

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Sandra P D'Angelo et al. J Immunother Cancer. 2021 Jul.

Abstract

Background: Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarker analyses from a cohort of patients with mMCC treated with first-line avelumab in a phase II trial.

Methods: Patients with treatment-naive mMCC received avelumab 10 mg/kg intravenously every 2 weeks. The primary endpoint was durable response, defined as objective response (complete or partial response; assessed by independent review) lasting ≥6 months. Additional assessments included progression-free survival (PFS), overall survival (OS), safety, and biomarker analyses.

Results: In 116 patients treated with avelumab, median follow-up was 21.2 months (range: 14.9-36.6). Thirty-five patients had a response lasting ≥6 months, giving a durable response rate of 30.2% (95% CI: 22.0% to 39.4%). The objective response rate was 39.7% (95% CI: 30.7% to 49.2%). Median PFS was 4.1 months (95% CI: 1.4 to 6.1) and median OS was 20.3 months (95% CI: 12.4 to not estimable). Response rates were numerically higher in patients with PD-L1+ tumors, Merkel cell polyomavirus (MCPyV)-negative tumors, and tumors with increased intratumoral CD8+ T-cell density. Exploratory analyses did not identify a biomarker that could reliably predict a response to first-line treatment with avelumab; however, a novel gene expression signature to identify the presence of MCPyV+ tumors was derived. Treatment-related adverse events (any grade) occurred in 94 (81.0%) patients, including grade 3/4 events in 21 (18.1%) patients; no treatment-related deaths occurred.

Conclusion: In patients with mMCC, first-line treatment with avelumab led to responses in 40% and durable responses in 30%, and was associated with a low rate of grade 3/4 treatment-related adverse events.

Trial registration: ClinicalTrials.gov NCT02155647.

Keywords: clinical trials; gene expression profiling; immunotherapy; phase II as topic; skin neoplasms; tumor biomarkers.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr D’Angelo reports serving as a consultant or advisor for Amgen, EMD Serono (an affiliate of Merck KGaA, Darmstadt, Germany), GlaxoSmithKline, Immune Design, Incyte, Merck & Co., and Nektar; received research grants from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck & Co., and Nektar; and received reimbursement for travel and accommodation expenses from Adaptimmune, EMD Serono, and Nektar. Dr Lebbé has received honoraria from Amgen, Bristol Myers Squibb, Incyte, Merck & Co., Novartis, Pfizer, Pierre Fabre, and Roche; reports serving as a consultant or advisor for Amgen, Bristol Myers Squibb, Merck & Co., Novartis, and Roche; is a member of a speakers bureau for Amgen, Bristol Myers Squibb, Novartis, and Roche; has received research funding from Bristol Myers Squibb and Roche; has received reimbursement for travel and accommodation expenses from Bristol Myers Squibb; and has other relationships with Avantis Medical Systems. Dr Mortier has received reimbursement for travel and accommodation expenses from Bristol Myers Squibb, Novartis, and Roche/Genentech. Dr Brohl reports serving as a consultant or advisor for Bayer, Deciphera, EMD Serono, and PierianDx. Dr Fazio has received honoraria from Ipsen and Novartis; reports serving as a consultant or advisor for Advanced Accelerator Applications, Ipsen, Merck KGaA, MSD Oncology, Novartis/Ipsen, and Pfizer; and has received research funding from Merck KGaA and Novartis. Dr Grob has received honoraria from Amgen, Bristol Myers Squibb, Merck KGaA, Merck & Co., Novartis, Pfizer, Pierre Fabre, Roche, and Sanofi; reports serving as a consultant or advisor for Amgen, Bristol Myers Squibb, Merck KGaA, Merck & Co., Novartis, Pfizer, Pierre Fabre, Roche, and Sanofi; is a member of a speakers’ bureau for Novartis; and has received reimbursement for travel and accommodation expenses from Bristol Myers Squibb, Merck & Co., Novartis, and Pierre Fabre. Dr Prinzi has received reimbursement for travel and accommodation expenses from Novartis. Dr Hanna has received research funding from Bristol Myers Squibb, Exicure, GlaxoSmithKline, Kite Pharma, NantKwest/Altor BioScience, Regeneron Pharmaceuticals, Sanofi Genzyme, and Kartos Therapeutics; and reports receiving honoraria and serving as a consultant for Bio-Rad Laboratories, Bristol Myers Squibb, Kura Oncology, Maverick Therapeutics, Merck KGaA, Prelude Therapeutics, and Regeneron Pharmaceuticals/Sanofi. Dr Hassel has received honoraria from Bristol Myers Squibb, Merck & Co., Novartis, Pfizer, and Roche; reports serving as a consultant or advisor for Merck & Co. and Pierre Fabre; has received research funding from 4SC, Amgen, BioNTech, Bristol Myers Squibb, Immunocore, Novartis, Philogen, and Roche; and has received reimbursement for travel and accommodation expenses from Pierre Fabre. Dr Kiecker has received honoraria from Amgen, Bristol Myers Squibb, Merck & Co., Novartis, Pierre Fabre, and Roche; reports serving as a consultant or advisor for Amgen, Bristol Myers Squibb, Incyte, Merck & Co., Novartis, and Roche; has received research funding from Novartis; and has received reimbursement for travel and accommodation expenses from Bristol Myers Squibb and Novartis. Dr Georges reports employment at EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Darmstadt, Germany. Ms Ellers-Lenz reports employment at Merck KGaA, Darmstadt, Germany. Dr Shah reports employment at EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Darmstadt, Germany. Dr Güzel reports employment at Merck KGaA, Darmstadt, Germany. Dr Nghiem has received honoraria from EMD Serono and Merck & Co.; reports serving as a consultant or advisor for EMD Serono and Pfizer; has received research funding from Bristol Myers Squibb and EMD Serono; and has a pending patent for high-affinity T-cell receptors that target the Merkel cell polyomavirus.

Figures

Figure 1
Figure 1
Clinical activity of avelumab. (A) Time to and duration of response for patients with an objective response according to IRC per RECIST 1.1 (n=46). (B) Kaplan-Meier estimate of overall survival (N=116). (C) DRR and (D) ORR in selected patient subgroups. CR, complete response; DRR, durable response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IRC, independent review committee; MCPyV, Merkel cell polyomavirus; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST 1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SLD, sum of longest diameters.
Figure 2
Figure 2
Association of MHC class I gene expression with CD8+ T-cell density at the (A) invasive margin and (B) the tumor core and (C) MHC class I gene expression in normal tissue and MCC tumor samples (figure shows HLA-A expression). The boxes represent interquartile ranges, and the horizontal lines are medians. The whiskers denote the lower and upper quartiles, and the circles represent data points. CPM, counts per million; GTEx, Genotype-Tissue Expression; HLA, human leukocyte antigen; MCC, Merkel cell carcinoma; MHC, major histocompatibility complex; TPM, transcripts per kilobase per million.
Figure 3
Figure 3
Expression profile according to MCPyV status. IHC, immunohistochemistry; MCPyV, Merkel cell polyomavirus; NA, not applicable.
See this image and copyright information in PMC

References

    1. NCCN Clinical Practice Guidelines in Oncology . Merkel cell carcinoma. V1.2020. Accessed October 17, 2020. Available: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf
    1. Harms KL, Healy MA, Nghiem P, et al. . Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol 2016;23:3564–71. 10.1245/s10434-016-5266-4 - DOI - PMC - PubMed
    1. Nghiem P, Kaufman HL, Bharmal M, et al. . Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol 2017;13:1263–79. 10.2217/fon-2017-0072 - DOI - PMC - PubMed
    1. Miller NJ, Church CD, Dong L, et al. . Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol Res 2017;5:137–47. 10.1158/2326-6066.CIR-16-0210 - DOI - PMC - PubMed
    1. Paulson KG, Iyer JG, Tegeder AR, et al. . Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011;29:1539–46. 10.1200/JCO.2010.30.6308 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data